To the best of our knowledge, this is the first report indicating that JQ1 showed anti-cancer effects through downregulation of SCG5, SPOCD1, RGS19, and ARHGAP22. We also found that these genes were good independent predictors for OS in patients with ccRCC. Here, ARHGAP22 is linked to nonpapillary renal cell carcinoma.